clinical trial · NCT04534699
Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
Moderate Hepatic ImpairmentHealthyKBP-5074
brief summary
This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of KBP-5074.
started
Aug 27, 2020
primary completion
Nov 19, 2020
completion
Nov 19, 2020
last updated
Dec 16, 2025
official title
A Phase 1, Open Label, Nonrandomized, Single-dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 in Subjects With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol